Soki Kashima, MD, PhD
Associate Research ScientistAbout
Research
Publications
Featured Publications
Update on Biomarkers in Renal Cell Carcinoma.
Saliby R, Saad E, Kashima S, Schoenfeld D, Braun D. Update on Biomarkers in Renal Cell Carcinoma. American Society Of Clinical Oncology Educational Book 2024, 44: e430734. PMID: 38207251, DOI: 10.1200/edbk_430734.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRenal cell carcinomaCell carcinomaMetastatic renal cell carcinomaTumor intrinsic featuresImmune checkpoint inhibitorsRobust predictive biomarkersCheckpoint inhibitorsDurable responsesOverall survivalCare regimensPathological characteristicsPredictive biomarkersTherapeutic responseTreatment paradigmImmune systemHost factorsTranscriptional signatureGenomic alterationsTumor heterogeneityBiomarkersCarcinomaBiomarker discoveryInnovative technological approachesRegimensThe Changing Landscape of Immunotherapy for Advanced Renal Cancer
Kashima S, Braun D. The Changing Landscape of Immunotherapy for Advanced Renal Cancer. Urologic Clinics Of North America 2023, 50: 335-349. PMID: 36948676, DOI: 10.1016/j.ucl.2023.01.012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRenal cell carcinomaAdvanced renal cell carcinomaCell carcinomaCentral therapeutic strategyAdvanced renal cancerDurable clinical benefitImmune checkpoint inhibitorsImmunecheckpoint inhibitorsCheckpoint inhibitorsCytokine therapyImmunogenic tumorsMost patientsSystemic therapyClinical benefitCombination therapyCurrent therapiesInterleukin-2Renal cancerTherapeutic strategiesTherapyCarcinomaInhibitorsImmunotherapyPatientsInterferonCytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model
Kashima S, Maeda T, Masuda K, Nagano S, Inoue T, Takeda M, Kono Y, Kobayashi T, Saito S, Higuchi T, Ichise H, Kobayashi Y, Iwaisako K, Terada K, Agata Y, Numakura K, Saito M, Narita S, Yasukawa M, Ogawa O, Habuchi T, Kawamoto H. Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model. IScience 2020, 23: 100998. PMID: 32259478, PMCID: PMC7188741, DOI: 10.1016/j.isci.2020.100998.Peer-Reviewed Original ResearchCytotoxic T lymphocytesPatient-derived xenograft modelsRenal cell carcinomaXenograft modelSolid tumorsT cellsT lymphocytesCurrent adoptive T cell therapiesTherapeutic efficacyWT1-specific cytotoxic T lymphocytesAdoptive T cell therapyT-cell therapyPatient T cellsSolid tumor modelsModels of leukemiaOrthotopic xenograft modelAutologous settingWT1 antigenCell carcinomaTumor modelAllogeneic approachCell therapyTumor growthAntigen-SpecificIPS cellsRegeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes
Maeda T, Nagano S, Kashima S, Terada K, Agata Y, Ichise H, Ohtaka M, Nakanishi M, Fujiki F, Sugiyama H, Kitawaki T, Kadowaki N, Takaori-Kondo A, Masuda K, Kawamoto H. Regeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes. Molecular Therapy — Methods & Clinical Development 2020, 19: 250-260. PMID: 33102617, PMCID: PMC7566080, DOI: 10.1016/j.omtm.2020.09.011.Peer-Reviewed Original ResearchCytotoxic T lymphocytesTumor antigen-specific cytotoxic T lymphocytesT-iPSCsT cell receptorT cellsT lymphocytesWT1-specific cytotoxic T lymphocytesExogenous T-cell receptorsAdoptive T cell therapyT-cell receptor genesT-cell therapyPatient T cellsAllogeneic T cellsT cell-derivedPluripotent stem cellsTreatment failureTCR genesCell therapyCell receptorsStem cellsIPSCsPatientsCell linesDifferentiation capabilityCellsFaithful preclinical mouse models for better translation to bedside in the field of immuno-oncology
Saito R, Kobayashi T, Kashima S, Matsumoto K, Ogawa O. Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology. International Journal Of Clinical Oncology 2019, 25: 831-841. PMID: 31407168, DOI: 10.1007/s10147-019-01520-z.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPreclinical mouse modelsMouse modelPrediction of immune-related adverse eventsPreclinical settingExploration of combination therapiesImmune-related adverse eventsCancer cell line-derived xenograftsCell line-derived xenograftsAutochthonous tumor modelImmunologically humanized micePatient-derived-xenograftsPredictive biomarker developmentImmune checkpoint inhibitorsSuccess of immunotherapyMurine tumor cell linesMicroenvironment of human cancersPractice of cancer treatmentCheckpoint inhibitorsTumor cell linesHumanized miceImmune microenvironmentCombination therapyImmuno-oncologyClinical featuresPreclinical studiesMyeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma
Bi K, Kashima S, Camp S, Meli K, Saad E, Titchen B, Labaki C, Bakouny Z, Pimenta E, Park J, Shannon E, Fu J, Xirenayi S, Horst J, Lum L, Ishizuka J, Choueiri T, Braun D, Van Allen E. Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma. Immunity 2025, 58: 2814-2829.e9. PMID: 41175876, PMCID: PMC12616721, DOI: 10.1016/j.immuni.2025.10.013.Peer-Reviewed Original ResearchConceptsImmune checkpoint blockadeRenal cell carcinomaTumor immune microenvironmentResistance to immunotherapyT cell killingIFNG signalingCell carcinomaMyeloid cellsIFN-stimulated genesMechanisms of resistance to immune checkpoint blockadeResistance to immune checkpoint blockadeRenal cell carcinoma tumor cellsImmune checkpoint blockade efficacyAdvanced renal cell carcinomaTumor cells in vitroAnti-VEGF therapyClinical trial cohortCells in vitroMultiple mechanismsEffect of IFNCheckpoint blockadeAnti-VEGFImmune checkpointsTrial cohortTumor cells
2026
Investigating mechanisms of resistance to immune checkpoint inhibitors (ICIs) in renal cell carcinoma (RCC).
Kashima S, Braun D, Rout R, Ye Z, Laughlin C, Schindler N, Malik R, Sun M, Lee G, Xu W, Signoretti S, Hurwitz M, Adeniran A, Humphrey P, Kenney P, McGregor B, McKay R, Gan L, DeWall S, Choueiri T. Investigating mechanisms of resistance to immune checkpoint inhibitors (ICIs) in renal cell carcinoma (RCC). Journal Of Clinical Oncology 2026, 44: 4545-4545. DOI: 10.1200/jco.2026.44.16_suppl.4545.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsRenal cell carcinomaT cell functionT cellsMechanisms of resistance to immune checkpoint inhibitorsNon-respondersResistance to immune checkpoint inhibitorsAssociated with shorter PFSICI responseImmune checkpoint inhibitor resistanceTumor-specific T cellsCD8 T cell infiltrationTGFB signalingRenal cell carcinoma tumorsICI-based therapyCD8 T cellsT cell infiltrationObserved-to-expected (O/E) ratioTumor microenvironment featuresLandmark clinical trialsT cell abundanceClinical trial cohortHuman T cellsNR tumoursCheckpoint inhibitorsCorrelation between CARINH expression and clinical outcomes in metastatic clear-cell renal cell carcinoma (mccRCC).
Khatoun W, Saad E, Masri J, Saleh M, Barrios P, Labaki C, Kane H, Meli K, Saliby R, Malik R, Chehade R, Ascione L, Kashima S, Sun M, Van Allen E, Braun D, Choueiri T. Correlation between CARINH expression and clinical outcomes in metastatic clear-cell renal cell carcinoma (mccRCC). Journal Of Clinical Oncology 2026, 44: 4553-4553. DOI: 10.1200/jco.2026.44.16_suppl.4553.Peer-Reviewed Original ResearchProgression-free survivalProgression-free survival predictionImmune signaturesLog-rank testMyeloid signatureClinical outcomesTreatment armsMetastatic clear-cell renal cell carcinomaExpression groupTreated with systemic therapyClear-cell renal cell carcinomaImmunogenic natureRenal cell carcinomaLow expression groupIMDC riskMccRCC patientsSarcomatoid featuresSystemic therapyCell carcinomaEsophageal cancerCox analysisMccRCCInflammatory scoreTumor growthClinical trialsAge-stratified outcomes of radical cystectomy for muscle-invasive bladder cancer: a nationwide multicenter study of 1867 patients in Japan
Kawai T, Miki J, Taoka R, Saito R, Fukuokaya W, Matsui Y, Fujii Y, Hatakeyama S, Kawahara T, Matsuda A, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Nakayama M, Matsumoto T, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Fujii M, Nishihara K, Kobayashi K, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Kume H, Group T. Age-stratified outcomes of radical cystectomy for muscle-invasive bladder cancer: a nationwide multicenter study of 1867 patients in Japan. Japanese Journal Of Clinical Oncology 2026, hyaf218. PMID: 41543041, DOI: 10.1093/jjco/hyaf218.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerRadical cystectomyNeoadjuvant chemotherapyOncological outcomesPerformance statusBladder cancerEastern Cooperative Oncology Group performance statusOutcomes of radical cystectomyPreoperative clinical T stageAge-stratified outcomesAssociated with better OSOutcomes of RCClinical T stageIncidence of gradePositive surgical marginsCancer-specific survivalGood performance statusDisease-free survivalMulti-institutional cohortMultivariate Cox analysisExtravesical extensionSurgical marginsOverall survivalT stageUnfavorable OS
2025
Androgen‐Deprivation Therapy and Dietary Habits Influence the Gut Microbial Environment in Patients With High‐Risk Localized Prostate Cancer
Ishida M, Narita S, Sato H, Sekine Y, Kobayashi M, Kashima S, Yamamoto R, Numakura K, Saito M, Takahashi Y, Funahashi K, Yamauchi Y, Fukuda S, Habuchi T. Androgen‐Deprivation Therapy and Dietary Habits Influence the Gut Microbial Environment in Patients With High‐Risk Localized Prostate Cancer. The Prostate 2025, 86: 515-524. PMID: 41389040, DOI: 10.1002/pros.70109.Peer-Reviewed Original ResearchHigh-risk localized prostate cancerAndrogen deprivation therapyLocalized prostate cancerPolyunsaturated Fatty Acid IntakeProstate cancerFatty acid intakePost-ADTDietary habitsAndrogen deprivationGut microbial profilesTotal testosteroneN-3 polyunsaturated fatty acid intakeN-6 polyunsaturated fatty acid intakeShort-term androgen deprivation therapyAcid intakeTS levelsAdvanced prostate cancerOccurrence of side effectsGut microbiotaRuminococcus 2Low TS levelsN-3 polyunsaturated fatty acidsMicrobial profilesNo significant differenceN-3
Academic Achievements & Community Involvement
News
News
- June 02, 2026
Yale Cancer Center Researchers and Trainees Present at 2026 ASCO Annual Meeting
- July 16, 2025
Yale Researchers Develop Novel Antibody-RNA Therapy for Resistant Cancers
- September 23, 2024Source: OncLive
Dr Kashima on T-Cell Phenotypes Associated With ICI Response/Resistance in RCC
- June 07, 2024
Yale Cancer Center Researchers and Trainees Present at ASCO
Get In Touch
Contacts
Locations
Center of Molecular and Cellular Oncology
Lab
300 George Street, Fl 6th Floor, Ste Suite 6109
New Haven, CT 06511